NICE confirms limits on Alimta for lung cancer
This article was originally published in Scrip
Executive Summary
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.